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Background: Neoadjuvant chemoradiation therapy (nCRT) has become the standard of care for esophageal cancer patients prior to esophagectomy. However, the optimal timing for surgery after completion of nCRT remains unclear. Methods: A retrospective review was performed of patients who underwent esophagectomy with cervical anastomosis for esophageal cancer at a single institution between January 2000 and June 2015. Patients were categorized into 3 cohorts: those who did not receive nCRT prior to esophagectomy (no nCRT), those who underwent esophagectomy within 35 days after nCRT (≤35d), and those who underwent esophagectomy more than 35 days after nCRT (＞35d). Results: A total of 366 esophagectomies were per-formed during the study period, and 348 patients met the inclusion criteria. Anastomotic leaks occurred in 11.8% of all patients included in the study (41 of 348). Within each cohort, anastomotic leaks were detected in 14.7% of patients (17 of 116) in the no nCRT cohort, 7.3% (13 of 177) in the ≤35d cohort, and 20.0% (11 of 55) in the ＞35d cohort (p=0.020). Significant differences in the occurrence of anastomotic leaks were observed between the no nCRT and ≤35d cohorts (p=0.044), and between the ≤35d and ＞35d cohorts (p=0.007). Conclusion: Esophagectomy with cervical anastomosis within 35 days of nCRT resulted in a lower percentage of anastomotic leaks.
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IntroductionNeoadjuvant chemoradiation therapy (nCRT) fol-lowed by surgery is a common treatment for locally advanced esophageal cancer. Recent studies have suggested that this treatment may improve survival 
and provide better local control [1-11], although sev-eral reports have shown no significant benefit [12-16]. Despite these inconsistencies, routine nCRT prior to esophagectomy is becoming a standard practice.There are concerns that nCRT may make surgery 
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more difficult because it can cause fibrosis and in-crease postoperative complications [17]. Moreover, nCRT could potentially influence the rates of anasto-motic leaks, which are a complication of esoph-agectomy associated with serious morbidity and mor-tality [18]. However, a recent multicenter study showed that nCRT had no impact on anastomotic leaks in patients who underwent surgery 6–8 weeks after completing treatment [19]. Further, a study by Kim et al. [20] demonstrated that perioperative mor-bidity and mortality did not differ for esophagec-tomies performed less than or more than 8 weeks following nCRT treatment. Although combined-modal-ity treatment regimens may lead to better outcomes, the data currently available are not conclusive re-garding the optimal timing of surgery following nCRT, and prior studies have not specifically focused on the implications of anastomotic leaks [20-25]. The aim of our study was to determine whether the tim-ing of esophagectomy following nCRT affected the in-cidence of anastomotic leaks.
MethodsThis study was reviewed and approved by the Institutional Review Board and informed consent was waived. A prospectively collected database of all pa-tients undergoing esophagectomy for esophageal can-cer from January 2000 to June 2015 at the University of Iowa Hospitals and Clinics was retrospectively reviewed. The histological subtypes of esophageal cancer included adenocarcinoma, squamous cell, neu-roendocrine, poorly differentiated, and gastrointestinal stromal tumor. Patients with a cervical esoph-agogastric anastomosis were included in the study; patients with an intrathoracic anastomosis were excluded. A detailed chart review was performed and the following data were recorded for each patient: age/sex; smoking history; previous history of dia-betes, chronic obstructive pulmonary disease (COPD), coronary artery disease (CAD), renal failure, or hy-pertension; prior abdominal/thoracic surgery; prior esophageal surgery; prior coronary artery bypass graft (CABG); weight loss greater than 4.5 kg; and body mass index (BMI). As part of staging, all pa-tients underwent computerized tomography scanning of the chest and abdomen, positron emission tomog-raphy scanning, and endoscopic ultrasonography.
1) Patient categorizationClinically significant anastomotic leaks were de-fined as any anastomoses that required drainage, and/or neck wound infections requiring jejunal feeds and/or parenteral nutrition. Cervical anastomoses were performed using the modified Collard technique. Briefly, the anastomosis was performed by stapling the posterior wall with an endo GIA stapler (Medtronic, Minneapolis, MN, USA) and oversewing the anterior wall with 2 absorbable monofilament layers of suture. Patients underwent a thin barium esophagram on postoperative day 5–7. All patients with a leak identified on the esophagram were in-cluded in the leak group. Patients with neck wounds that were erythematous and/or draining had the in-cisions opened at the bedside and were considered to have anastomotic leaks.Patients with identified anastomotic leaks were divided into 3 cohorts based on the timing of esoph-agectomy: those who did not receive nCRT (no CRT), those who underwent esophagectomy within 35 days of completing nCRT (≤35d), and those who under-went esophagectomy more than 35 days after nCRT (＞35d). The cutoff point for being at an increased risk for an anastomotic leak rate following nCRT was determined using logistic regression, which was per-formed by analyzing all of the patients who devel-oped an anastomotic leak and taking each time point in days from surgery to determine whether there was an increased risk for a leak. The time point when there was a trend towards a greater risk for an anastomotic leak was calculated. Patients who un-derwent surgery more than 35 days after nCRT had a higher risk of an anastomotic leak than those who underwent surgery at 35 days or less (odds ratio, 2.95; 95% confidence interval [CI], 1.25–7.00; p=0.014).
2) Statistical analysisCategorical data were analyzed using the chi-square test or the Fisher exact test, as appropriate. Con-tinuous variables were analyzed using analysis of variance. Intergroup comparisons of quantitative vari-ables were analyzed using the Kruskal-Wallis test. Data were expressed as number of patients, with the percentage in parentheses, or median with inter-quartile range. Statistical significance was defined as p＜0.05. Statistical analyses were performed using IBM SPSS ver. 24.0 (IBM Corp., Armonk, NY, USA). 
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Esophagectomy ≤35 days 
post-nCRT (n=177)
Esophagectomy ＞35 days 
post-nCRT (n=55)
p-valuea)
Age at surgery (yr) 66.7±11.4 (32–88) 61.0±9.6 (25–82) 60.3±9.7 (27–79) ＜0.001b)
Sex (male) 92 (79) 149 (84) 49 (89) 0.252
Never smoked 31 (27) 34 (19) 9 (16) 0.447
Ever smoked
Current smoker 24 (21) 40 (23) 15 (27)
Former smoker 61 (52) 103 (58) 31 (56)
Diabetes 20 (17) 36 (20) 11 (20) 0.796
Chronic obstructive pulmonary disease 15 (13) 21 (12) 4 (7) 0.565c)
Coronary artery disease 25 (22) 31 (18) 15 (27) 0.272
Renal failure 3 (3) 2 (1) 1 (2) 0.543c)
Hypertension 66 (57) 85 (48) 29 (53) 0.327
Prior abdominal surgery 55 (47) 61 (35) 19 (35) 0.066
Prior thoracic surgery 11 (10) 15 (9) 4 (7) 0.901c)
Prior esophageal surgery 8 (7) 6 (3) 1 (2) 0.296c)
Prior coronary artery bypass graft 10 (9) 13 (7) 6 (11) 0.699
Weight loss ＞4.5 kg 39 (34) 120 (68) 29 (53) ＜0.001
Body mass index at surgery (kg/m2) 28.8±6.4 (16.0–45.6) 27.7±6.4 (14.2–57.8) 27.7±6.4 (18.7–50.2) 0.360d)
Values are presented as mean±standard deviation (min–max) or number (%).
nCRT, neoadjuvant chemoradiotherapy.
a)By chi-square test. b)By Kruskal-Wallis. c)By Fisher exact test. d)By analysis of variance.
Actuarial survival rates for the 3 cohorts were calcu-lated using the Kaplan-Meier method.
ResultsWithin the timeframe of this study, a total of 366 esophagectomies were performed to treat esophageal cancer. The most common type of procedure per-formed was transhiatal esophagectomy (n=330). Other techniques included the Mckeown 3-hole esophagectomy (n=25) and the Ivor Lewis esoph-agectomy (n=11). Several patients were excluded, for the following reasons: the 11 patients who under-went an Ivor Lewis esophagectomy were excluded due to the presence of an intrathoracic anastomosis, 5 patients were excluded due to delayed cervical anastomosis after spit fistula formation during the in-itial operation, and 2 patients were excluded because radiation therapy was administered with curative in-tent at high doses (6,000 cGy and 7,440 cGy). Intrathoracic anastomoses were excluded, as the ma-jority of our patients had cervical anastomoses and intrathoracic anastomoses only occurred in a small fraction (＜5%) of our cohort. The small number 
would only confound the data and would not allow a meaningful comparison.A total of 348 patients met the inclusion criteria. Overall, 348 anastomoses were assessed for leaks us-ing radiographic imaging unless clinical evidence of a leak was present. The median dose of radiation was 5,040 cGy (range, 4,140–5,600 cGy). Chemotherapy consisted of a platinum-based regimen; the most common agents used were cisplatin/5-fluorouracil and carboplatin/paclitaxel. The median time to sur-gery after completion of neoadjuvant treatment was 28 days. The 30-day operative mortality rate was 2.3% (8 of 348).Patients were divided into 3 cohorts based on the timing of surgery following nCRT: no nCRT cohort, 
≤35d cohort, and ＞35d cohort. The cutoff of 35 days was determined using logistic regression to de-termine the time at which the incidence of anasto-motic leaks increased. Table 1 summarizes the demo-graphic characteristics for each cohort. The patho-logic staging of the tumors for each cohort is sum-marized in Table 2. The mean age of patients who did not receive nCRT was higher (66.7 years) than that of patients who received nCRT (60.3 years in 
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Table 2. Pathologic staging of all patients who underwent esophagectomy in this study
TNM staging
Esophagectomy without nCRT 
(n=116)
Esophagectomy ≤35 days 
post-nCRT (n=177)
Esophagectomy ＞35 days 
post-nCRT (n=55)
T0 - 45 (25.4) 21 (38.2)
Tis 18 (15.5) 6 (3.4) -
T1 35 (30.2) 19 (10.7) 7 (12.7)
T2 15 (12.9) 32 (18.1) 12 (21.8)
T3 38 (32.8) 73 (41.2) 14 (25.5)
T4 10 (8.6) 2 (1.1) 1 (1.8)
N0 68 (58.6) 119 (67.2) 38 (69.1)
N1 34 (29.3) 33 (18.6) 16 (29.1)
N2 10 (8.6) 21 (11.9) 1 (1.8)
N3 4 (3.4) 4 (2.3) -
Complete response - 41 (23.2) 19 (34.5)
Stage 0 18 (15.5) 6 (3.4) -
Stage IA/B, IIA 38 (32.8) 39 (22.0) 14 (25.5)
Stage IIB 23 (19.8) 46 (26.0) 11 (20.0)
Stage IIIA 17 (14.7) 22 (12.4) 10 (18.2)
Stage IIIB 8 (6.9) 19 (10.7) 1 (1.8)
Stage IIIC 12 (10.3) 4 (2.3) -
Values are presented as number (%).
TNM, tumor–node–metastasis; nCRT, neoadjuvant chemoradiotherapy.
Table 3. Timing of esophagectomy after nCRT and its effect on anastomotic leak incidence
Timing of nCRT With anastomotic leak p-valuea) Pairwise comparison
Post-hoc adjusted 
p-value
No nCRT (n=116) 17 (14.7) 0.020 No nCRT vs. ≤35 days 0.044
nCRT ≤35 days prior to surgery (n=177) 13 (7.3) No nCRT vs. ＞35 days 0.378
nCRT ＞35 days prior to surgery (n=55) 11 (20.0) ≤35 days vs. ＞35 days 0.007
Values are presented as number (%), unless otherwise stated.
nCRT, neoadjuvant chemoradiotherapy.
a)By chi-square test.
the ＞35d cohort and 61.0 years in the ≤35d co-hort; p＜0.001). No differences in sex, smoking his-tory, diabetes, COPD, CAD, renal failure, hypertension, prior abdominal/thoracic surgery, prior esophageal surgery, prior CABG, and BMI were observed among the cohorts. Weight loss of over 4.5 kg was more common in patients who received nCRT (53% in the 
＞35d cohort and 68% in the ≤35d cohort) than in those in the no nCRT group (33%, p＜0.001).Among all patients who were included, anasto-motic leaks occurred in 11.8% (41 of 348). Among the 41 patients with anastomotic leaks, 11 leaks (26.8%) were found radiographically on the initial evaluation. The neck incision was opened at the bed-side if a patient had clinical signs of a cervical anas-
tomotic leak, and no further radiographic examina-tion was performed. Anastomotic leaks were ob-served in 10.3% of patients (24 of 232) who re-ceived nCRT, but in 14.7% (17 of 116) of no nCRT group (p=0.247). A comparison of anastomotic leaks among the 3 cohorts demonstrated a significant dif-ference between the no nCRT cohort and the ≤35d cohort (p=0.044), whereas no significant difference was observed between the no nCRT and ＞35d co-horts (p=0.378). When esophagectomy was per-formed within 35 days of nCRT, anastomotic leaks occurred in 7.3% of patients (13 of 177), whereas they occurred in 20.0% of patients (11 of 55) who had surgery more than 35 days following nCRT (p=0.007) (Table 3). Among the patients who re-
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Table 4. Effects of anastomotic leaks on the median length of the hospital stay and on 30-day operative mortality
Variable Anastomotic leak (n=41) No anastomotic leak (n=307) p-value
Median length of stay (25th–75th percentile) (day) 20 (9.5–29) 6 (5–9) ＜0.001
No. of 30-day operative mortality (%) 3 (7.3) 5 (1.6) 0.056
Table 6. Effects of timing of nCRT on median length of the hospital stay and on 30-day operative mortality
Variable
Esophagectomy ≤35 days 
after nCRT (n=177)
Esophagectomy ＞35 days 
after nCRT (n=55)
p-value
Median length of stay (25th–75th percentile) (day) 6 (5–8) 7 (6–13) ＜0.001
No. of 30-day operative mortality (%) 2 (1.1) 0 0.581
nCRT, neoadjuvant chemoradiotherapy.
Table 5. Effects of nCRT on the median length of the hospital stay and on 30-day operative mortality among patients with an anasto-
motic leak
Variable
Anastomotic leak with nCRT 
(n=24)
Anastomotic leak without nCRT 
(n=17)
p-value
Median length of stay (25th–75th percentile) (day) 10 (7.3–21.8) 26 (18–64.5) 0.041
No of 30-day operative mortality (%) 0 3 (17.6) 0.064
nCRT, neoadjuvant chemoradiotherapy.
Fig. 1. Kaplan-Meier curve for overall survival (p=0.101). nCRT, 
neoadjuvant chemoradiotherapy.
ceived nCRT, the median time to surgery after com-pletion of treatment was longer (35 days) for those with an anastomotic leak than for those who had no detectable leak (28 days).The median hospital stay following surgery was longer among patients with an anastomotic leak (20 days) than those without a leak (6 days, p＜0.001). The 30-day operative mortality rate was 7.3% (3 of 41) for patients with an anastomotic leak and 1.6% (5 of 307) for patients without an anastomotic leak (p=0.056) (Tables 4–6). The median survival by group was 52.3 months (95% CI, 26.5–78.1 months) in the no nCRT cohort, 38.7 months (95% CI, 20.0–57.3 months) in the ≤35d cohort, and 24.2 months (95% CI, 18.4–30.1 months) in the ＞35d cohort, (p=0.101) (Fig. 1). The 5-year survival rates were 49.1% (57 of 116) in the no nCRT cohort, 46.9% (83 of 177) in the ≤35d cohort, and 30.9% (17 of 55) in the ＞35d cohort. The 90-day mortality rates were 10.3% (12 of 116) in the no nCRT cohort, 3.4% (6 of 177) in the ≤35d cohort, and 10.9% (6 of 55) in the ＞35d cohort.
DiscussionCurrently, the effects of nCRT on postoperative complications following esophagectomy are unclear. In some retrospective studies, neoadjuvant therapy was found to be associated with postoperative com-plications [5,26]. For example, adverse effects on work-ing capacity were observed in a retrospective trial in 
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which surgical resection was performed 4–6 weeks after the completion of neoadjuvant therapy [26]. In contrast, other studies have failed to find any neg-ative effects on surgical morbidity [1,2,12-15,19,27]. Randomized trials comparing surgery alone to neo-adjuvant chemo-radiotherapy have failed to demon-strate any adverse effects of nCRT therapy on surgi-cal complications [11,16]. In these trials, resection was performed within 3–4 weeks of completion of nCRT, and patients’ survival improved. In a retro-spective trial that demonstrated harm following neo-adjuvant therapy, surgical resection was frequently performed 4-6 weeks after neoadjuvant therapy was completed [26].Extending the time between nCRT and esoph-agectomy has been theorized to increase tumor re-gression, leading to improved tumor resectability and an increase in the pathologic complete response (pCR). Some studies have concluded that a longer in-terval between nCRT and esophagectomy resulted in higher rates of pCR [23,25], whereas others have re-ported no significant improvement [20-22]. In a mul-ticenter trial in Europe, no difference in the occur-rence of anastomotic leaks was observed when sur-gery was performed 6–8 weeks after the completion of nCRT therapy [19]. Additionally, a study by Kim et al. [20] found no significant difference in post-operative morbidity and mortality in esophagectomies performed within or after 8 weeks of receiving nCRT.In contrast, a report that evaluated the 30- and 90-day mortality rates after esophagectomy using da-ta from the American College of Surgeons National Cancer Database found a positive effect on operative mortality when esophagectomy was delayed after ne-oadjuvant therapy (90 days versus 30 days) [24]. The results from our study suggest that a short delay (≤35 days) in esophagectomy after the completion of nCRT reduces the occurrence of anastomotic leaks. Patients who did not receive nCRT were also noted to have a higher rate of anastomotic leaks than those in the ≤35d group. No nCRT group was significantly older, with a mean age of 66.7 years, than the pa-tients in the ≤35d group, who had a mean age of 61.0 years. While older age may have been a con-tributing factor to the higher anastomotic leak rate among patients who did not receive nCRT, age alone is unlikely to be the only contributing factor. This is a limitation of the study, and further investigation is 
needed to identify factors leading to differences in the leak rate between these 2 cohorts.This study specifically analyzed the effects of tim-ing of nCRT prior to surgery on the rate of anasto-motic leaks, whereas prior studies have analyzed perioperative complications more generally. Our data showing that patients who underwent surgery within 35 days of nCRT had a lower rate of anastomotic leaks provide a clear time frame during which to perform surgery after nCRT. Furthermore, anasto-motic leaks significantly increased the length of the hospital stay post-esophagectomy compared to pa-tients who did not have a leak. However, differences in the occurrence of anastomotic leaks due to nCRT did not affect overall survival; no difference in the survival rate was observed between patients who re-ceived nCRT and those who did not (Fig. 1). Thus, our data suggest that reducing the time to esoph-agectomy following nCRT to less than 35 days pos-itively affects postoperative outcomes such as the oc-currence of anastomotic leaks. However, each patient must be evaluated on an individual basis, accounting for all clinical variables such as performance status, in order to determine the best time for surgery after nCRT.Although prior studies have used 30 days, 60 days, 90 days, 4 weeks, or 8 weeks after nCRT as the time frame for surgery, our study categorized 35 days as the cutoff between the 2 groups of patients who re-ceived nCRT. This cutoff period was derived by per-forming a logistic regression analysis of the data to determine when patients started to have an in-creased incidence of anastomotic leaks. Patients were categorized into quartiles, which resulted in the fol-lowing classifications of days after nCRT to surgery: 12–23 days, 24–28 days, 29–35 days, and ＞35 days. The ＞35 days group showed a significantly in-creased rate of anastomotic leaks. This time frame may not be equivalent to that used in prior studies, but one of the primary goals of this study was to ex-amine the effect of timing after nCRT prior to sur-gery and its impact on anastomotic leaks. Therefore, having a time frame distinct from those used in pre-viously reported studies was justified.Although our data demonstrate a reduction in the number of anastomotic leaks in patients who had a preoperative interval of ≤35 days following com-pletion of nCRT, some limitations should be kept in 
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mind. This study was performed retrospectively and did not account for differences in baseline demo-graphics (such as patient age) or in preoperative weight loss between those who did or did not re-ceive nCRT. Confounding variables such as pre-operative albumin and transfusion requirements, which can affect the occurrence of anastomotic leaks, were not collected in the database [28]. Our dataset also did not include tumor regression response data, and we were thus unable to analyze how the timing of esophagectomy following nCRT affected tumor response. In addition, patients undergoing surgery 
＞35 days after nCRT may have had worse perform-ance status, resulting in both delayed surgery and a higher incidence of leaks. Further investigation is needed to determine the factors associated with the increased anastomotic leak rates in this cohort of patients.Our analysis did not include information on the ra-diation field used during neoadjuvant radiation therapy. The size of the radiation field can have a significant impact on development of anastomotic leakage, espe-cially if the cranial level of the radiation field in-cludes the location of the cervical anastomosis. The exact cranial level of the radiation field could not be determined for many members of our patient cohort, as some underwent neoadjuvant radiation therapy at another institution, due to proximity and the pa-tient’s convenience. Although the radiation field in-corporated the malignancy and there were limited variations on the field extending beyond the margins of the tumor, a lack of quantification of the radiation field is a limitation of the study.The study spans more than 15 years of data, and there may have been differences in decision-making in terms of the operators’ choice of surgical techni-que and in the preoperative and postoperative man-agement of patients that could have affected the in-cidence of anastomotic leaks. We also recognize that the vascularity of the gastric conduit and tension placed during anastomosis may have varied among the operators and patients included in the study. However, given the rigorous training that all oper-ators underwent, as well as the standardization of surgical technique, anastomoses were performed only if there was adequate blood supply to the gastric conduit, and they were performed in a way that minimized tension on the conduit. These factors 
were not readily quantifiable retrospectively, which represents another limitation of the study.Despite these limitations, our current practice has incorporated the findings of our study, so that esoph-agectomies are now performed within 35 days of nCRT. Further investigation will help to determine the optimal time interval during which to proceed with surgery following nCRT, as well as characteriz-ing the effects of this timing on tumor regression and overall survival.
Conflict of interestNo potential conflict of interest relevant to this ar-ticle was reported.
ORCIDSimon Roh: https://orcid.org/0000-0003-0530-6634Mark D. Iannettoni: https://orcid.org/0000-0003-3413-8609John Keech: https://orcid.org/0000-0001-8153-0211Evgeny V. Arshava: https://orcid.org/0000-0003-2146-4990Ronald J. Weigel: https://orcid.org/0000-0002-9249-0793Kalpaj R. Parekh: https://orcid.org/0000-0001-6869-5441
References
1. Urschel JD, Vasan H. A meta-analysis of randomized con-
trolled trials that compared neoadjuvant chemoradiation 
and surgery to surgery alone for resectable esophageal 
cancer. Am J Surg 2003;185:538-43.
2. Gebski V, Burmeister B, Smithers BM, et al. Survival bene-
fits from neoadjuvant chemoradiotherapy or chemo-
therapy in oesophageal carcinoma: a meta-analysis. Lancet 
Oncol 2007;8:226-34.
3. Van Hagen P, Hulshof MC, van Lanschot JJ, et al. 
Preoperative chemoradiotherapy for esophageal or junc-
tional cancer. N Engl J Med 2012;366:2074-84.
4. Bekkar S, Gronnier C, Messager M, et al. The impact of 
preoperative radiochemotherapy on survival in advanced 
esophagogastric junction signet ring cell adenocarcinoma. 
Ann Thorac Surg 2014;97:303-10.
5. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy 
followed by surgery compared with surgery alone in squ-
amous-cell cancer of the esophagus. N Engl J Med 1997; 
337:161-7.
6. Hong JC, Murphy JD, Wang SJ, Koong AC, Chang DT. 
Chemoradiotherapy before and after surgery for locally 
advanced esophageal cancer: a SEER-Medicare analysis. 
Ann Surg Oncol 2013;20:3999-4007.
7. Knox JJ, Wong R, Visbal AL, et al. Phase 2 trial of pre-
Simon Roh, et al
− 8 −
operative irinotecan plus cisplatin and conformal radio-
therapy, followed by surgery for esophageal cancer. 
Cancer 2010;116:4023-32.
8. Oppedijk V, van der Gaast A, van Lanschot JJ, et al. 
Patterns of recurrence after surgery alone versus pre-
operative chemoradiotherapy and surgery in the CROSS 
trials. J Clin Oncol 2014;32:385-91.
9. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival 
after neoadjuvant chemotherapy or chemoradiotherapy 
for resectable oesophageal carcinoma: an updated 
meta-analysis. Lancet Oncol 2011;12:681-92.
10. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of 
trimodality therapy with cisplatin, fluorouracil, radio-
therapy, and surgery compared with surgery alone for 
esophageal cancer: CALGB 9781. J Clin Oncol 2008;26: 
1086-92.
11. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, 
Hennessy TP. A comparison of multimodal therapy and 
surgery for esophageal adenocarcinoma. N Engl J Med 
1996;335:462-7.
12. Hamai Y, Hihara J, Taomoto J, Yamakita I, Ibuki Y, Okada 
M. Effects of neoadjuvant chemoradiotherapy on post-
operative morbidity and mortality associated with esoph-
ageal cancer. Dis Esophagus 2015;28:358-64.
13. Kumagai K, Rouvelas I, Tsai JA, et al. Meta-analysis of 
postoperative morbidity and perioperative mortality in 
patients receiving neoadjuvant chemotherapy or chemo-
radiotherapy for resectable oesophageal and gastro-oeso-
phageal junctional cancers. Br J Surg 2014;101:321-38.
14. Lin FC, Durkin AE, Ferguson MK. Induction therapy does 
not increase surgical morbidity after esophagectomy for 
cancer. Ann Thorac Surg 2004;78:1783-9.
15. Merritt RE, Whyte RI, D’Arcy NT, Hoang CD, Shrager JB. 
Morbidity and mortality after esophagectomy following 
neoadjuvant chemoradiation. Ann Thorac Surg 2011;92: 
2034-40.
16. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, 
Strawderman M. Randomized trial of preoperative chemo-
radiation versus surgery alone in patients with locore-
gional esophageal carcinoma. J Clin Oncol 2001;19:305-13.
17. Delanian S, Lefaix JL. Current management for late nor-
mal tissue injury: radiation-induced fibrosis and necrosis. 
Semin Radiat Oncol 2007;17:99-107.
18. Iannettoni MD, Whyte RI, Orringer MB. Catastrophic com-
plications of the cervical esophagogastric anastomosis. J 
Thorac Cardiovasc Surg 1995;110:1493-500.
19. Gronnier C, Trechot B, Duhamel A, et al. Impact of neo-
adjuvant chemoradiotherapy on postoperative outcomes 
after esophageal cancer resection: results of a European 
multicenter study. Ann Surg 2014;260:764-70.
20. Kim JY, Correa AM, Vaporciyan AA, et al. Does the timing 
of esophagectomy after chemoradiation affect outcome? 
Ann Thorac Surg 2012;93:207-12.
21. Ruol A, Rizzetto C, Castoro C, et al. Interval between neo-
adjuvant chemoradiotherapy and surgery for squamous 
cell carcinoma of the thoracic esophagus: does delayed 
surgery have an impact on outcome? Ann Surg 2010;252: 
788-96.
22. Tessier W, Gronnier C, Messager M, et al. Does timing of 
surgical procedure after neoadjuvant chemoradiation af-
fect outcomes in esophageal cancer? Ann Thorac Surg 
2014;97:1181-9.
23. Shaikh T, Ruth K, Scott WJ, et al. Increased time from neo-
adjuvant chemoradiation to surgery is associated with 
higher pathologic complete response rates in esophageal 
cancer. Ann Thorac Surg 2015;99:270-6.
24. Franko J, Voynov G, Goldman CD. Esophagectomy timing 
after neoadjuvant therapy for distal esophageal 
adenocarcinoma. Ann Thorac Surg 2016;101:1123-30.
25. Lee A, Wong AT, Schwartz D, Weiner JP, Osborn VW, 
Schreiber D. Is there a benefit to prolonging the interval 
between neoadjuvant chemoradiation and esophagectomy 
in esophageal cancer? Ann Thorac Surg 2016;102:433-8.
26. Liedman B, Johnsson E, Merke C, Ruth M, Lundell L. 
Preoperative adjuvant radiochemotherapy may increase 
the risk in patients undergoing thoracoabdominal esoph-
ageal resections. Dig Surg 2001;18:169-75.
27. Berger AC, Farma J, Scott WJ, et al. Complete response to 
neoadjuvant chemoradiotherapy in esophageal carcinoma 
is associated with significantly improved survival. J Clin 
Oncol 2005;23:4330-7.
28. Dewar L, Gelfand G, Finley RJ, Evans K, Inculet R, Nelems 
B. Factors affecting cervical anastomotic leak and stric-
ture formation following esophagogastrectomy and gas-
tric tube interposition. Am J Surg 1992;163:484-9.
